Correction: The Board of Directors of Ortivus AB withdraws the proposal to the Annual General Meeting on 8 May 2025 regarding authorisation for the Board to issue shares, etc.

The correction concerns classification as Regulatory solely in accordance with listing requirements.

The Board of Directors of Ortivus AB has resolved to withdraw its proposal that the Board be granted authorisation by the Annual General Meeting to issue class B shares, etc. The proposal is withdrawn in its entirety.

Furthermore, the Board has decided to make a minor adjustment to the proposed amendment to the Articles of Association concerning the number of class A shares that may be issued.

Previous wording
“Shares may be either class A shares or class B shares. Class A shares may be issued in a number not exceeding 5,120,000 and class B shares in a number not exceeding 160,000,000.”

Revised proposed wording
“Shares may be either class A shares or class B shares. Class A shares may be issued in a number not exceeding 6,000,000 and class B shares in a number not exceeding 160,000,000.”

In all other respects, the Board’s proposal regarding the amendment to the Articles of Association remains unchanged.

The Annual General Meeting will be held at Ortivus’ office in Danderyd on 8 May 2025 at 15:00.

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in real-time, MobiMed ePR, – an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, – a tool for navigation and case management, and MobiMed Life – a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market.

Read more about Ortivus at www.ortivus.com

The Board of Directors of Ortivus AB withdraws the proposal to the Annual General Meeting on 8 May 2025 regarding authorisation for the Board to issue shares, etc.